ArticleCancer immunology, immunotherapy : CII2025
Molecular subtyping dictates therapeutic response to anti-PD-L1 immunotherapy in ES-SCLC.
Qianqian Zhang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
3 papers cite it
this paperpooled itcites it